CLL Self-Advocacy: 5 Steps to Empower Your Care

Chronic Lymphocytic Leukemia (CLL) is often indolent but requires active partnership with your care team for optimal outcomes.

Five Advocacy Pillars

1. Become an Expert on Your Disease:
   • Learn CLL biology (B-cell malignancy), staging (Rai/Binet), prognostic markers (del17p, TP53 mut, IGHV, complex karyotype).
   • Trusted sources: NCCN Guidelines, CLL Society, ASH, Lymphoma Research Foundation.
   • Understand "Watch & Wait" — active surveillance is standard for asymptomatic early-stage.
2. Build a Collaborative Care Team:
   • CLL-specialist hematologist/oncologist (academic or high-volume community).
   • Prepare questions; bring notebook/recorder; request visit summaries.
   • Second opinions are standard — seek at diagnosis, progression, or treatment crossroads.
3. Participate in Treatment Decisions:
   • Ask: "What are my options? What do guidelines recommend for my markers? What are trial options?"
   • BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib), BCL-2 inhibitor (venetoclax), anti-CD20 — understand mechanisms, durations, toxicities.
   • Time-limited vs. continuous therapy — align with your goals.
4. Access Support Ecosystems:
   • CLL Society support groups (virtual/in-person), peer mentors.
   • Financial: copay foundations (PAN, HealthWell), drug manufacturer programs.
   • Caregiver support — they need resources too.
5. Adopt a Long-Game Mindset:
   • CLL is a marathon. Monitor trends (lymphocytes, nodes, symptoms) not single values.
   • Vaccinations (non-live), infection prevention, skin cancer screening (↑ risk).
   • Advance care planning early — not when crisis hits.

Key Questions for Every Visit

• Has my genetic risk profile changed?
• Am I a candidate for time-limited therapy (venetoclax + obinutuzumab)?
• What is my MRD status?
• How do we manage (specific side effect)?